financetom
Business
financetom
/
Business
/
Tesla's First-Quarter Deliveries to Take Further Hit From Softness in China, Deutsche Bank Says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Tesla's First-Quarter Deliveries to Take Further Hit From Softness in China, Deutsche Bank Says
Mar 28, 2024 10:23 AM

12:45 PM EDT, 03/28/2024 (MT Newswires) -- Deutsche Bank on Thursday lowered its Tesla (TSLA) delivery estimates for the second time in less than three weeks, citing weaker-than-expected sales in China and the electric vehicle maker's plan to cut production in the region.

The brokerage cut its first-quarter delivery outlook to 414,000 units from 427,000 vehicles due to lower sales in China in the last few weeks of March. Analysts surveyed by Visible Alpha are modeling deliveries of 454,100 units for the first quarter.

Deutsche Bank's full-year estimate was reduced to 1.9 million deliveries from 1.96 million units, now representing mid-single digit growth versus a high-single-digit increase previously expected, Deutsche Bank said in a note emailed Thursday. The consensus on Visible Alpha is 2.03 million units.

"We continue to see pressure on margins and earnings, as the company already announced deep price cuts in both China and Europe earlier in the quarter, and made further moderate price adjustments in February to incentivize vehicle purchases," Deutsche Bank analyst Emmanuel Rosner said.

Rosner previously cut Tesla's estimates on March 11. Tesla's share price has lost nearly 29% so far this year amid a slowdown in the EV market.

Tesla has announced price increases in the US and China effective in April. However, the move appears "as an attempt to boost sales in March, rather than a sign of solid demand," Rosner said Thursday.

Price: 177.43, Change: -2.40, Percent Change: -1.34

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Canadian Imperial Bank Of Commerce, Bank of Nova Scotia, Bank of Montreal Ratings Affirmed by Fitch
Canadian Imperial Bank Of Commerce, Bank of Nova Scotia, Bank of Montreal Ratings Affirmed by Fitch
Jun 18, 2024
10:37 AM EDT, 06/18/2024 (MT Newswires) -- Fitch Ratings has affirmed the long-term issuer default rating and short-term issuer default rating on Canadian Imperial Bank Of Commerce's ( CM ) , Bank of Nova Scotia's ( BNS ) , and Bank of Montreal's ( NRGD ) at AA- and F1+, respectively. Also, Fitch affirmed the ratings of the bank's subsidiaries...
JAKKS Pacific's Disguise Unit Signs Multi-Year Licensing Deal With Aniplex of America
JAKKS Pacific's Disguise Unit Signs Multi-Year Licensing Deal With Aniplex of America
Jun 18, 2024
10:37 AM EDT, 06/18/2024 (MT Newswires) -- JAKKS Pacific's ( JAKK ) Disguise business unit said Tuesday that it signed a multi-year licensing agreement with Aniplex of America covering the Demon Slayer: Kimetsu no Yaiba animated series in North America, Australia, New Zealand, LATAM, Ireland, and the UK. The deal allows Disguise to design, develop, and manufacture costume accessories based...
O-I Glass to Invest $65 Million in Electrification, Decarbonization Project for Plant in France
O-I Glass to Invest $65 Million in Electrification, Decarbonization Project for Plant in France
Jun 18, 2024
10:34 AM EDT, 06/18/2024 (MT Newswires) -- O-I Glass ( OI ) said Tuesday it plans to invest about $65 million into the electrification and decarbonization of its plant in Veauche, France. The company said one of its two furnaces will be renovated and fitted with hybrid-flex technology. The project will give the company the flexibility to replace up to...
Intra-Cellular Therapies' Highlights Successful Data From Second Depression Study
Intra-Cellular Therapies' Highlights Successful Data From Second Depression Study
Jun 18, 2024
Tuesday, Intra-Cellular Therapies Inc ( ITCI ) released topline results from Study 502 evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD).  The company expects to submit a supplemental FDA application in the second half of 2024. Lumateperone 42 mg, given once daily as adjunctive therapy to antidepressants, met the primary...
Copyright 2023-2026 - www.financetom.com All Rights Reserved